Delal Akdeniz1, Marjanka K Schmidt2, Caroline M Seynaeve3, Danielle McCool4, Daniele Giardiello5, Alexandra J van den Broek6, Michael Hauptmann4, Ewout W Steyerberg7, Maartje J Hooning8. 1. Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, Netherlands; Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Division of Molecular Pathology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands. 2. Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Division of Molecular Pathology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands. 3. Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, Netherlands. 4. Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands. 5. Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Department of Medical Statistics and Bioinformatics, Leiden University Medical Centre, Leiden, Netherlands. 6. Division of Molecular Pathology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands. 7. Department of Public Health, Erasmus MC, Rotterdam, Netherlands; Department of Medical Statistics and Bioinformatics, Leiden University Medical Centre, Leiden, Netherlands. 8. Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, Netherlands. Electronic address: m.hooning@erasmusmc.nl.
Abstract
BACKGROUND: The risk of developing metachronous contralateral breast cancer (CBC) is a recurrent topic at the outpatient clinic. We aimed to provide CBC risk estimates of published patient, pathological, and primary breast cancer (PBC) treatment-related factors. METHODS: PubMed was searched for publications on factors associated with CBC risk. Meta-analyses were performed with grouping of studies by mutation status (i.e., BRCA1, BRCA2, CHEK2 c.1100delC), familial cohorts, and general population-based cohorts. RESULTS: Sixty-eight papers satisfied our inclusion criteria. Strong associations with CBC were found for carrying a BRCA1 (RR = 3.7; 95%CI:2.8-4.9), BRCA2 (RR = 2.8; 95%CI:1.8-4.3) or CHEK2 c.1100delC (RR = 2.7; 95%CI:2.0-3.7) mutation. In population-based cohorts, PBC family history (RR = 1.8; 95%CI:1.2-2.6), body mass index (BMI) ≥30 kg/m2 (RR = 1.5; 95%CI:1.3-1.9), lobular PBC (RR = 1.4; 95%CI:1.1-1.8), estrogen receptor-negative PBC (RR = 1.5; 95%CI:1.0-2.3) and treatment with radiotherapy <40 years (RR = 1.4; 95%CI:1.1-1.7) was associated with increased CBC risk. Older age at PBC diagnosis (RR per decade = 0.93; 95%CI:0.88-0.98), and treatment with chemotherapy (RR = 0.7; 95%CI:0.6-0.8) or endocrine therapy (RR = 0.6; 95%CI:0.5-0.7) were associated with decreased CBC risk. CONCLUSIONS: Mutation status, family history, and PBC treatment are key factors for CBC risk. Age at PBC diagnosis, BMI, lobular histology and hormone receptor status have weaker associations and should be considered in combination with key factors to accurately predict CBC risk.
BACKGROUND: The risk of developing metachronous contralateral breast cancer (CBC) is a recurrent topic at the outpatient clinic. We aimed to provide CBC risk estimates of published patient, pathological, and primary breast cancer (PBC) treatment-related factors. METHODS: PubMed was searched for publications on factors associated with CBC risk. Meta-analyses were performed with grouping of studies by mutation status (i.e., BRCA1, BRCA2, CHEK2c.1100delC), familial cohorts, and general population-based cohorts. RESULTS: Sixty-eight papers satisfied our inclusion criteria. Strong associations with CBC were found for carrying a BRCA1 (RR = 3.7; 95%CI:2.8-4.9), BRCA2 (RR = 2.8; 95%CI:1.8-4.3) or CHEK2c.1100delC (RR = 2.7; 95%CI:2.0-3.7) mutation. In population-based cohorts, PBC family history (RR = 1.8; 95%CI:1.2-2.6), body mass index (BMI) ≥30 kg/m2 (RR = 1.5; 95%CI:1.3-1.9), lobular PBC (RR = 1.4; 95%CI:1.1-1.8), estrogen receptor-negative PBC (RR = 1.5; 95%CI:1.0-2.3) and treatment with radiotherapy <40 years (RR = 1.4; 95%CI:1.1-1.7) was associated with increased CBC risk. Older age at PBC diagnosis (RR per decade = 0.93; 95%CI:0.88-0.98), and treatment with chemotherapy (RR = 0.7; 95%CI:0.6-0.8) or endocrine therapy (RR = 0.6; 95%CI:0.5-0.7) were associated with decreased CBC risk. CONCLUSIONS: Mutation status, family history, and PBC treatment are key factors for CBC risk. Age at PBC diagnosis, BMI, lobular histology and hormone receptor status have weaker associations and should be considered in combination with key factors to accurately predict CBC risk.
Authors: Nita H Mukand; Naomi Y Ko; Nadia A Nabulsi; Colin C Hubbard; Brian C-H Chiu; Kent F Hoskins; Gregory S Calip Journal: Breast Cancer Date: 2021-11-19 Impact factor: 4.239
Authors: D Brock Hewitt; Yaming Li; Oindrila Bhattacharyya; James L Fisher; Daniel Stover; Samilia Obeng-Gyasi Journal: J Racial Ethn Health Disparities Date: 2022-04-06
Authors: Daniele Giardiello; Maartje J Hooning; Michael Hauptmann; Renske Keeman; B A M Heemskerk-Gerritsen; Heiko Becher; Carl Blomqvist; Stig E Bojesen; Manjeet K Bolla; Nicola J Camp; Kamila Czene; Peter Devilee; Diana M Eccles; Peter A Fasching; Jonine D Figueroa; Henrik Flyger; Montserrat García-Closas; Christopher A Haiman; Ute Hamann; John L Hopper; Anna Jakubowska; Floor E Leeuwen; Annika Lindblom; Jan Lubiński; Sara Margolin; Maria Elena Martinez; Heli Nevanlinna; Ines Nevelsteen; Saskia Pelders; Paul D P Pharoah; Sabine Siesling; Melissa C Southey; Annemieke H van der Hout; Liselotte P van Hest; Jenny Chang-Claude; Per Hall; Douglas F Easton; Ewout W Steyerberg; Marjanka K Schmidt Journal: Breast Cancer Res Date: 2022-10-21 Impact factor: 8.408
Authors: Daniele Giardiello; Ewout W Steyerberg; Michael Hauptmann; Muriel A Adank; Delal Akdeniz; Carl Blomqvist; Stig E Bojesen; Manjeet K Bolla; Mariël Brinkhuis; Jenny Chang-Claude; Kamila Czene; Peter Devilee; Alison M Dunning; Douglas F Easton; Diana M Eccles; Peter A Fasching; Jonine Figueroa; Henrik Flyger; Montserrat García-Closas; Lothar Haeberle; Christopher A Haiman; Per Hall; Ute Hamann; John L Hopper; Agnes Jager; Anna Jakubowska; Audrey Jung; Renske Keeman; Iris Kramer; Diether Lambrechts; Loic Le Marchand; Annika Lindblom; Jan Lubiński; Mehdi Manoochehri; Luigi Mariani; Heli Nevanlinna; Hester S A Oldenburg; Saskia Pelders; Paul D P Pharoah; Mitul Shah; Sabine Siesling; Vincent T H B M Smit; Melissa C Southey; William J Tapper; Rob A E M Tollenaar; Alexandra J van den Broek; Carolien H M van Deurzen; Flora E van Leeuwen; Chantal van Ongeval; Laura J Van't Veer; Qin Wang; Camilla Wendt; Pieter J Westenend; Maartje J Hooning; Marjanka K Schmidt Journal: Breast Cancer Res Date: 2019-12-17 Impact factor: 6.466
Authors: Daniele Giardiello; Iris Kramer; Maartje J Hooning; Michael Hauptmann; Esther H Lips; Elinor Sawyer; Alastair M Thompson; Linda de Munck; Sabine Siesling; Jelle Wesseling; Ewout W Steyerberg; Marjanka K Schmidt Journal: NPJ Breast Cancer Date: 2020-11-03
Authors: Jelle Wesseling; Michael Schaapveld; Maartje van Seijen; Esther H Lips; Liping Fu; Daniele Giardiello; Frederieke van Duijnhoven; Linda de Munck; Lotte E Elshof; Alastair Thompson; Elinor Sawyer; Marc D Ryser; E Shelley Hwang; Marjanka K Schmidt; Paula H M Elkhuizen Journal: Br J Cancer Date: 2021-08-18 Impact factor: 7.640
Authors: Inge M M Lakeman; Alexandra J van den Broek; Juliën A M Vos; Daniel R Barnes; Julian Adlard; Irene L Andrulis; Adalgeir Arason; Norbert Arnold; Banu K Arun; Judith Balmaña; Daniel Barrowdale; Javier Benitez; Ake Borg; Trinidad Caldés; Maria A Caligo; Wendy K Chung; Kathleen B M Claes; J Margriet Collée; Fergus J Couch; Mary B Daly; Joe Dennis; Mallika Dhawan; Susan M Domchek; Ros Eeles; Christoph Engel; D Gareth Evans; Lidia Feliubadaló; Lenka Foretova; Eitan Friedman; Debra Frost; Patricia A Ganz; Judy Garber; Simon A Gayther; Anne-Marie Gerdes; Andrew K Godwin; David E Goldgar; Eric Hahnen; Christopher R Hake; Ute Hamann; Frans B L Hogervorst; Maartje J Hooning; John L Hopper; Peter J Hulick; Evgeny N Imyanitov; Claudine Isaacs; Louise Izatt; Anna Jakubowska; Paul A James; Ramunas Janavicius; Uffe Birk Jensen; Yue Jiao; Esther M John; Vijai Joseph; Beth Y Karlan; Carolien M Kets; Irene Konstantopoulou; Ava Kwong; Clémentine Legrand; Goska Leslie; Fabienne Lesueur; Jennifer T Loud; Jan Lubiński; Siranoush Manoukian; Lesley McGuffog; Austin Miller; Denise Molina Gomes; Marco Montagna; Emmanuelle Mouret-Fourme; Katherine L Nathanson; Susan L Neuhausen; Heli Nevanlinna; Joanne Ngeow Yuen Yie; Edith Olah; Olufunmilayo I Olopade; Sue K Park; Michael T Parsons; Paolo Peterlongo; Marion Piedmonte; Paolo Radice; Johanna Rantala; Gad Rennert; Harvey A Risch; Rita K Schmutzler; Priyanka Sharma; Jacques Simard; Christian F Singer; Zsofia Stadler; Dominique Stoppa-Lyonnet; Christian Sutter; Yen Yen Tan; Manuel R Teixeira; Soo Hwang Teo; Alex Teulé; Mads Thomassen; Darcy L Thull; Marc Tischkowitz; Amanda E Toland; Nadine Tung; Elizabeth J van Rensburg; Ana Vega; Barbara Wappenschmidt; Peter Devilee; Christi J van Asperen; Jonine L Bernstein; Kenneth Offit; Douglas F Easton; Matti A Rookus; Georgia Chenevix-Trench; Antonis C Antoniou; Mark Robson; Marjanka K Schmidt Journal: Genet Med Date: 2021-06-10 Impact factor: 8.864
Authors: Iris Kramer; Maartje J Hooning; Nasim Mavaddat; Michael Hauptmann; Renske Keeman; Ewout W Steyerberg; Daniele Giardiello; Antonis C Antoniou; Paul D P Pharoah; Sander Canisius; Zumuruda Abu-Ful; Irene L Andrulis; Hoda Anton-Culver; Kristan J Aronson; Annelie Augustinsson; Heiko Becher; Matthias W Beckmann; Sabine Behrens; Javier Benitez; Marina Bermisheva; Natalia V Bogdanova; Stig E Bojesen; Manjeet K Bolla; Bernardo Bonanni; Hiltrud Brauch; Michael Bremer; Sara Y Brucker; Barbara Burwinkel; Jose E Castelao; Tsun L Chan; Jenny Chang-Claude; Stephen J Chanock; Georgia Chenevix-Trench; Ji-Yeob Choi; Christine L Clarke; J Margriet Collée; Fergus J Couch; Angela Cox; Simon S Cross; Kamila Czene; Mary B Daly; Peter Devilee; Thilo Dörk; Isabel Dos-Santos-Silva; Alison M Dunning; Miriam Dwek; Diana M Eccles; D Gareth Evans; Peter A Fasching; Henrik Flyger; Manuela Gago-Dominguez; Montserrat García-Closas; José A García-Sáenz; Graham G Giles; David E Goldgar; Anna González-Neira; Christopher A Haiman; Niclas Håkansson; Ute Hamann; Mikael Hartman; Bernadette A M Heemskerk-Gerritsen; Antoinette Hollestelle; John L Hopper; Ming-Feng Hou; Anthony Howell; Hidemi Ito; Milena Jakimovska; Anna Jakubowska; Wolfgang Janni; Esther M John; Audrey Jung; Daehee Kang; C Marleen Kets; Elza Khusnutdinova; Yon-Dschun Ko; Vessela N Kristensen; Allison W Kurian; Ava Kwong; Diether Lambrechts; Loic Le Marchand; Jingmei Li; Annika Lindblom; Jan Lubiński; Arto Mannermaa; Mehdi Manoochehri; Sara Margolin; Keitaro Matsuo; Dimitrios Mavroudis; Alfons Meindl; Roger L Milne; Anna Marie Mulligan; Taru A Muranen; Susan L Neuhausen; Heli Nevanlinna; William G Newman; Andrew F Olshan; Janet E Olson; Håkan Olsson; Tjoung-Won Park-Simon; Julian Peto; Christos Petridis; Dijana Plaseska-Karanfilska; Nadege Presneau; Katri Pylkäs; Paolo Radice; Gad Rennert; Atocha Romero; Rebecca Roylance; Emmanouil Saloustros; Elinor J Sawyer; Rita K Schmutzler; Lukas Schwentner; Christopher Scott; Mee-Hoong See; Mitul Shah; Chen-Yang Shen; Xiao-Ou Shu; Sabine Siesling; Susan Slager; Christof Sohn; Melissa C Southey; John J Spinelli; Jennifer Stone; William J Tapper; Maria Tengström; Soo Hwang Teo; Mary Beth Terry; Rob A E M Tollenaar; Ian Tomlinson; Melissa A Troester; Celine M Vachon; Chantal van Ongeval; Elke M van Veen; Robert Winqvist; Alicja Wolk; Wei Zheng; Argyrios Ziogas; Douglas F Easton; Per Hall; Marjanka K Schmidt Journal: Am J Hum Genet Date: 2020-10-05 Impact factor: 11.025